Plain-English translation of NCT04650321 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Multiple Sclerosis research guide →Phase 4 — The treatment has already been approved. Researchers are tracking how it works in a large number of people over time.
This trial is testing whether ocrelizumab, a medication used to treat multiple sclerosis, can be safely given to patients at home instead of in a hospital or clinic setting. The study will monitor how well the treatment works and whether patients experience any side effects or negative reactions when receiving the medication at home. Researchers will also ask participants about their experiences and quality of life before and after receiving the treatment.
During and after the COVID-19 pandemic, many patients found it difficult or risky to travel to clinics for regular medical infusions. This trial explores whether this medication can be safely delivered at home, making treatment more convenient and accessible for people with multiple sclerosis.
You likely qualify if…
You likely don't qualify if…
If you qualify, you will receive your regular multiple sclerosis medication infusion at your home instead of at the clinic—a nurse or healthcare provider will come to you to administer the treatment. Before and after your home infusion, you will be asked to fill out short surveys or questionnaires about how you are feeling and your quality of life. Study staff will monitor you for any side effects or reactions to the medication, just as they would during a clinic visit.
AI-generated summary from trial data · Jun 10, 2026 · Not medical advice
United States
Phase
Post-approval monitoring
Sponsor
University of Colorado, Denver
Collaborators
Genentech, Inc.
Enrollment target
~110 participants
Started
March 2021
Primary completion
August 2021
This trial's estimated completion date has passed — the record may not be fully up to date.
Age range
18 Years – 55 Years
Last updated on clinicaltrials.gov in June 2021.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Brooke Valdez, BS
University of Colorado, Denver
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.